Roles of the complement system in human neurodegenerative disorders: Pro-inflammatory and tissue remodeling activities

Molecular Neurobiology

Volumn 25, Issue 1, 2002, Pages 1-17

  Gasque, Philippe ^a   Neal, Jim W ^a   Singhrao, Sim K ^a   McGreal, Eamon P ^a   Dean, Yann D ^a   van Beek, Johan ^a   Morgan, B Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

CNS infection; Complement; Inflammation; Innate immunology; Neurodegeneration; Therapy

Indexed keywords

COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT; COMPLEMENT RECEPTOR; NERVE PROTEIN; OPSONIN;

BIOSYNTHESIS; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL LOSS; CENTRAL NERVOUS SYSTEM INFECTION; CHEMOTAXIS; COMPLEMENT SYSTEM; CYTOLYSIS; CYTOTOXICITY; DEGENERATIVE DISEASE; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; PHAGOCYTOSIS; REVIEW; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; COMPLEMENT ACTIVATION; DRUG SCREENING; GLIA; IMMUNOLOGY; INFLAMMATION; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS; OPSONIN PROTEINS; PHAGOCYTOSIS; RECEPTORS, COMPLEMENT;

EID: 0036182751     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:25:1:001     Document Type: Review

References (121)

1. The role of complement in inflammation and phagocytosis
2. The role of complement in disorders of the nervous system
3. Complement C1q and C3 messenger RNA expression in the frontal cortex of Alzheimer's patients
4. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain
5. Complement c1-inhibitor expression in Alzheimer's disease
6. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease
7. Neurons express proteins of the classical complement pathway in Alzheimer disease
8. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
9. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes
10. Identification and characterization of complement C3 receptors on human astrocytes
11. Characterisation of expression of complement receptor type 4 (CR4) by human glia
12. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system
13. C3aR is a marker of inflammation and gliosis in human neurodegenerative disorders
14. Expression of C3aR in man and mouse: Predominance in adrenal gland, skin and lung
15. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis
16. Expression of the C1q/MBL/SPA receptor involved in phagocytosis and innate immune defense on human glia
17. Expression of the receptors for the C5a anaphylatoxin interleukin-8 and FMLP by human astrocytes and microglia
18. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease
19. Production and interferon-gamma-mediated regulation of complement component C2 and factor-B and factor-D by the astroglioma cell-line U105-MG
20. Expression of the complement classical pathway by human glioma in culture: A model for complement expression by nerve cells
21. Interferon-gamma regulation of C3-gene expression in human astroglioma cells
22. Alzheimer amyloid plaque associated cytokines increase C1r and C1s, not C1-inhibitor, expression by human astrocytes and neuroblastoma cell lines in vitro
23. Expression of complement C4 and C9 genes by human astrocytes
24. Complement gene expression in neuroblastoma and astrocytoma cell lines of human origin
25. Expression of complement components of the alternative pathway by glioma cell lines
26. Detection of complement protein messenger RNA in human astrocytes by the polymerase chain reaction
27. Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene-expression in human astroglioma cells
28. Complement expression in human brain: Biosynthesis of terminal pathway components and regulators in human glial-cells and cell lines
29. Expression of a functional anaphylatoxin C3a receptor by astrocytes
30. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains
31. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells
32. Complement regulatory protein expression by a human oligodendrocyte cell line: Cytokine regulation and comparison with astrocytes
33. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue
34. Distribution of clusterin in Alzheimer brain tissue
35. Detection of the membrane inhibitor of reactive lysis (Cd59) in diseased neurons of Alzheimer brain
36. Differential expression of individual complement regulators in the brain and choroid plexus
37. Detection of mosaic protein messenger-RNA in human astrocytes
38. Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes
39. Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation
40. Complement expression on astrocytes and astrocytoma cell lines: Failure of complement regulation at the C3 level correlates with very low CD55 expression
41. Expression and regulation of decay-accelerating factor (Cd55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell-line, D54-Mg, and primary rat astrocytes
42. Production and regulation of decay-accelerating factor by the astroglioma cell line D54-MG
43. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes
44. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer's disease
45. Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins
46. Vitronectin expression in Purkinje cells in the human cerebellum
47. Human oligodendrocytes are not sensitive to complement: A study of CD59 expression in the human central nervous system
48. Extrahepatic complement biosynthesis: Where, when and why?
49. Nonimmune activation of the classical complement pathway
50. Complement activation in amyloid plaques in Alzheimers dementia
51. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimers dementia
52. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease
53. Activation of the classical complement pathway in brain tissue of Alzheimer's patients
54. Complement proteins, activators and inhibitors in Alzheimer's disease brain
55. An immunohistological study of the brain lesions in Alzheimer's disease and senile dementia of Alzheimer's type evidence of complement components in vascular and senile plaque amyloid
56. Complement activation in amyloid plaques in alzheimer's disease brains does not proceed further than C3
57. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
58. Immunohistochemical distribution of the inhibitors of the terminal complement complex in Alzheimer's disease
59. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A-chain
60. Complement activation by beta amyloid in Alzheimer's disease
61. In vitro analysis of C1 activation by A beta Alzheimer's disease-related peptides
62. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis
63. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide
64. Association of amyloid-P component with complement proteins in neurologically diseased brain tissue
65. Altered gene expression in Alzheimer's disease brain tissue
66. Dynamics of gene expression for a hippocampal glycoprotein elevated in alzheimer's disease and in response to experimental lesions in rat
67. Differences in gene expression in the cerebral cortex of Alzheimer's disease and agematched control brains
68. Astroglial gene expression in response to hippocampal deafferentation in the rat and in Alzheimer's disease
69. Complement gene expression in human brain comparison between normal and Alzheimer's disease cases
70. Up-regulated production and activation of the complement system in Alzheimer's disease brain
71. Complement messenger RNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning
72. Regional localisation of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease
73. Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies
74. Activation of complement by myelin: Identification of C1-binding proteins of human myelin from central nervous tissue
75. Role of complement in the aetiology of Pick's disease?
76. Expression of the complement membrane attack complex and its inhibitors in Pick disease brain
77. Membrane receptors for soluble defense collagens
78. Characterization of complement anaphylatoxins and their biological responses
79. Regulation in the complement system
80. Membrane proteins that protect against complement lysis
81. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
82. Complement biosynthesis in the central nervous system
83. Expression of complement in the brain: Role in health and disease
84. Primary cultures of murine astrocytes produce C-3 and Factor-B, 2 components of the alternative pathway of complement activation
85. Differential regulation of C3 gene-expression by gamma-interferon and interleukin-1 in the astroglioma cell-line, D54-MG
86. Gamma-interferon (IFN-gamma)-mediated regulation of C3 by D54-MG astroglioma cells and primary rat astrocytes
87. Differential regulation of C3 gene expression in human astroglioma cells by interferon-gamma and interleukin-1-beta
88. Detection and cellular localization of human C4 gene expression in the renal tubular epithelial cells and other extrahepatic epithelial sources
89. Gene expression in scrapie: Cloning a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts
90. Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either borna-disease or experimental allergic encephalomyelitis
91. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis
92. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis
93. Normal rat serum cytotoxicity against syngeneic oligodendrocytes: Complement activation and attack in the absence of anti-myelin antibodies
94. Killing of rat glial cells by complement deficiency of the rat analog of CD59 is the cause of oligodendrocyte susceptibility to lysis
95. The expression of complement regulatory proteins by adult human oligodendrocytes
96. CD59 expression and complement susceptibility of human neuronal cell line (NTera2)
97. Human neurons are lyed by complement because they spontaneous by activate the clinical pathway and lack membranic bound complement regulators
98. The expression of Cd59 in normal human nervous tissue
99. Translating cell biology into therapeutic advances in Alzheimer's disease
100. Localization and cell association of C1q in Alzheimer's disease brain
101. Huntington disease
102. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: Complemement deficiency and systemic lupus erythematous revisited
103. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse
104. Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement
105. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: Specific increase in interleukin-6 mRNA expression
106. Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells
107. Inflammatory signals induce neurotrophin expression in human microglial cells
108. C3a and C5a anaphylatoxins receptors
109. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects
110. Effects of the membrane attack complex of complement on nucleated cells
111. The role of terminal complement complexes in arachidonic-acid release from rat oligodendrocyte-X-C6 glioma cell hybrids
112. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent
113. Terminal complement complexes (TCC) activate GTP-binding regulatory proteins
114. Oligodendrocyte protection by sublytic C5b-9 from apoptotic cell death
115. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
116. Arachidonic-acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte x C-6 glioma cell hybrids
117. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition
118. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide
119. Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein
120. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
121. Inflammation and Alzheimer's disease: Therapeutic implications